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Abstract
Background: Depressive symptoms associated with bipolar disorder negatively impact health-related quality of life
(HRQoL). The efficacy of lurasidone in reducing depressive symptoms has been previously demonstrated. The objective
of this study was to examine the direct and indirect effect (mediated through improvement in depression symptoms)
of lurasidone in improving patient HRQoL.
Methods: A secondary analysis of data was conducted of two 6-week, double-blind, placebo-controlled trials assessing
the effect of lurasidone (lurasidone monotherapy [20–60 mg/day or 80–120 mg/day]; lurasidone adjunctive to lithium
or valproate [20–120 mg/day]) in patients with bipolar depression. Patient HRQoL was measured using the Quality of
Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q SF). Depression symptoms were measured using
the Montgomery-Asberg Depression Rating Scale (MADRS). Analysis of covariance (ANCOVA) was used to estimate the
effect of lurasidone on improvement in the Q-LES-Q SF percentage maximum score from baseline to 6 weeks. Path
analysis was used to evaluate the total effect (β1), as well as the indirect (β2*β3) and direct (β4) effect of lurasidone on
Q-LES-Q SF change through improvements in MADRS.
Results: A total of 340 and 485 patients from the monotherapy and adjunctive therapy, respectively, were included in
the analysis. At 6-weeks, ANCOVA analyses demonstrated that lurasidone provided significant improvement in adjusted
mean Q-LES-Q SF scores in comparison to placebo for monotherapy (22.9 and 22.7 vs. 15.2, both p < 0.01) and
adjunctive therapy (23.1 vs. 17.9, p = 0.01). Path analyses indicated that lurasidone treatment predicted MADRS
improvement (monotherapy: β2 = −0.44, p < 0.001; adjunctive therapy: β2 = −0.34, p = 0.003), which subsequently
predicted improvement in Q-LES-Q SF (monotherapy: β3 = −0.73, p < 0.001; adjunctive therapy: β3 = −0.75, p < 0.001);
however, the effect of lurasidone on improvement in Q-LES-Q SF was largely mediated by change in MADRS
(monotherapy: β4 = 0.11, p = 0.13; adjunctive therapy: β4 = 0.02, p = 0.77).
Conclusions: Lurasidone as a monotherapy and adjunctive to lithium or valproate is an effective treatment for
improving HRQoL in patients with bipolar depression. However, improvement in HRQoL was not independent of
improvement in depression, indicating that the effect of lurasidone on improving patient HRQoL may act through a
reduction in depressive symptoms associated with bipolar disorder.
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Background
Bipolar disorder is a chronic and debilitating mental
illness, characterized by recurrent mood fluctuations
between periods of depressive and manic symptoms,
with an estimated lifetime prevalence of 1.0 % [1, 2] and
is the 12th leading cause of disability worldwide [3].
Frequent episodes of depression represent the most
common symptomatic state in individuals with bipolar
disorder [4, 5], where depressive episodes are associated
with a greater negative impact on social, occupational,
and general functioning than episodes of mania [4, 6–8].
Consequently, health-related quality of life (HRQoL) is
also highly compromised in individuals with bipolar
depression, where patients with bipolar depression report
even greater worsening in their HRQoL and other indica-
tors of functioning than patients with other mood disor-
ders or mental illnesses [4, 9, 10].
Traditionally, clinical trials of treatment efficacy in
patients with bipolar depression have focused on symp-
tom remission (using the Diagnostic and Statistical
Manual-IV-TR [DSM-IV-TR] or clinician-reported
outcome assessments such as the Montgomery-Asberg
Depression Rating Scale [MADRS] score ≤10 to signify
remission status [11]). Increasingly, the ability of the
patient to perform activities of daily living, engage and
nurture social relationships, and function independently
are being considered when evaluating treatment efficacy
[4, 12, 13], as the burden of bipolar depression can
persist even in patients considered to be in symptomatic
remission [14, 15]. Given this, HRQoL assessments can
provide an additional indicator of improvement in areas
valued by the patient beyond symptomatic improvement
[16].
Relatively few clinical trials have incorporated patient-
reported outcome (PRO) measures to assess improve-
ment in HRQoL in drug registration trials, although the
number of studies incorporating these tools is increasing
given the increasingly holistic view of improving pa-
tient’s lives in treating chronic illnesses such as bipolar
disorder [4, 17]. A literature review conducted by Revicki
et al. in 2005 suggested that HRQoL may improve as a
result of treatment, although these studies were limited to
a short follow-up duration and small sample size [18].
More recently, IsHak et al. [19] expanded on previous
reviews to address if various forms of treatment (e.g., drug
therapy, behavioral therapy) have an impact on bipolar
disorder, demonstrating that several drug and psycho-
therapeutic treatment regimens were associated with
improved HRQoL in this patient population.
Only two medications were approved for the treat-
ment of acute bipolar depression as a monotherapy in
the United States until 2013 (e.g., combination of
olanzapine-fluoxetine and quetiapine) [20–22]. In two
placebo-controlled clinical trials, the atypical antipsychotic
lurasidone, approved by the US FDA as a monotherapy
and adjunctive to lithium or valproate, was found to
significantly improve symptoms of depression, HRQoL,
and other PROs in patients with bipolar depression over a
6-week period [23, 24]. Thus, positive benefits in areas of
life valued by the patient were achieved over the trial
period. However, it is important to know if PRO improve-
ments were a direct result of lurasidone treatment (a dir-
ect effect), or if this HRQoL improvement is achieved due
to reductions in symptoms of depression (a completely-
mediated indirect effect) or a combination of both, direct
and indirect effects. With this information, clinicians
and payors will have a much greater understanding of
the total effects associated with lurasidone treatment
on HRQoL. Thus, the aim of this study was to exam-
ine the direct and indirect effects (mediated through
improvement in bipolar depression symptoms) of lur-
asidone in improving patient HRQoL.
Methods
Study design and data source
A secondary analysis of data from two randomized,
6-week, multicenter, double-blind, placebo-controlled,
parallel-group studies conducted to assess the efficacy
of lurasidone as a treatment for bipolar depression
(NCT00868699 and NCT00868452) were used to assess
the direct and indirect effects of lurasidone on HRQoL
improvement. The study population in this analysis was
the intention-to-treat (ITT) population. For monotherapy,
the ITT population consisted of a total of 505 randomized
patients receiving at least one dose of study medication at
doses of 20–60 mg/day or 80–120 mg/day, with at least
one post-baseline efficacy measurement for the MADRS.
Following a washout period of at least 3 days, patients
were randomly assigned in a 1:1:1 ratio via an interactive
voice response system to receive 6 weeks of treatment
with lurasidone, at flexible daily doses of either 20–60 mg
or 80–120 mg, or 6 weeks of placebo. For adjunctive ther-
apy, the ITT population consisted of a total of 672 ran-
domized patients receiving at least one dose of study
medication at a dose of 20–120 mg/day adjunctive to lith-
ium or valproate, with at least one post-baseline efficacy
measurement for the MADRS. Patients underwent strati-
fied randomization, based on treatment with either lith-
ium or valproate, to either adjunctive lurasidone 20–
120 mg/day or placebo in a 1:1 ratio via an interactive
voice response system. The dose of mood stabilizer was
adjusted to maintain a serum level in the range of 0.6–
1.2 mEq/liter for lithium or 50–125 for valproate through-
out the study.
The patient population in both studies was adult patients
(≥18 years old) with bipolar I disorder. All patients were
experiencing a major depressive episode (DSM-IV-TR
criteria, ≥ 4 weeks and <12 months in duration), with or
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without rapid cycling, without psychotic features, and with
a history of at least one lifetime bipolar manic or mixed
manic episode. Diagnosis was confirmed by the Mini-
International Neuropsychiatric Interview [25] and the Bipo-
larity Index [26]. A MADRS [11] score ≥20 and a Young
Mania Rating Scale (YMRS) score ≤12 were required at
both screening and baseline. For both studies, efficacy
assessments were obtained at baseline and weekly intervals.
The primary efficacy endpoint was the mean change
from baseline to week 6 in MADRS total score. At each
study visit, a qualified site-based rater conducted the
MADRS assessment; a second MADRS assessment was
administered and scored by computer as part of a qual-
ity control process. Additional study design details,
including a comprehensive list of patient entry criteria,
as well as primary efficacy and safety analyses, have
been published elsewhere [23, 24].
The study was approved by an institutional review
board at each investigational site (from January 2009 to
May 2010) and was conducted in accordance with the
International Conference on Harmonisation Good Clin-
ical Practices guidelines and with the ethical principles
of the Declaration of Helsinki. Written informed
consent was obtained from all participants prior to
participation.
Scales and assessments included in this analysis
Symptom assessment
Montgomery Asberg Depression Rating Scale (MADRS)
The patient’s primary bipolar depression symptoms were
assessed using the MADRS, a clinician-administered
depression rating scale developed from a larger scale to be
sensitive to change [11]. The MADRS has 10 items, each
scored on a 0–6 scale. A score of 0 indicates an absence of
that symptom, and anchor point descriptors are given for
scores of 0, 2, 4, and 6. Items assess many facets of depres-
sion, including sadness, tension, pessimism, suicidal
thoughts, reduced sleep, and reduced appetite. A total
score of 60 is possible, indicating greater depression
severity.
Quality of life enjoyment and satisfaction questionnaire
short form
The Q-LES-Q SF is a 16-item HRQoL measure of the
degree of enjoyment and satisfaction experienced by pa-
tients in various areas of daily living [27]. The 16 items
reduce to eight summary scales that reflect major areas
of functioning: physical health, mood, leisure time activ-
ities, social relationships, general activities, work, house-
hold duties, and school/coursework. Each item is rated
on a 5-point scale, ranging from 1 (very poor) to 5 (very
good). The first 14 items are the same as the General
Activities section of the regular Q-LES-Q form and are
used to compute the raw score (Items 15 and 16 were
not used in the present analyses). The sum of scores for
items 1–14 can range from 14–70, and is expressed as a
percentage (0–100) of the maximum total score that is
achievable. Higher scores indicate better HRQoL.
The demographic and baseline characteristics of all
participants were summarized using descriptive statistics
(mean, standard deviation, range, frequencies for cat-
egorical variables). Descriptive statistics for the Q-LES-
Q SF and the MADRS were summarized at baseline. All
analyses were stratified by clinical trial (i.e., monotherapy
and adjunctive therapy).
Efficacy analyses
For the current analysis, mean change in Q-LES-Q SF
percentage maximum scores (ΔQ-LES-Q SF) from baseline
to 6 weeks was used to assess the efficacy of treatment on
HRQoL. Analysis of covariance analyses (ANCOVA) were
conducted, with fixed effects for treatment group, pooled
study center, and baseline score entered as covariates.
Pairwise comparisons between means were performed
using Scheffe's test adjusting for multiple comparisons.
Model effect estimates, standard errors (SE), and p-values
are presented for all analyses.
Path analysis
Path analysis was conducted for monotherapy and ad-
junctive therapy trials (collapsing across dosage groups)
to assess the relationship between treatment and ΔQ-
LES-Q SF directly and through ΔMADRS, following the
procedures described by Baron and Kenny [28]. The
Baron and Kenny mediation model assesses the degree
of the treatment effect upon a response variable in the
presence of another variable (i.e., the mediating vari-
able). This approach allows the examination of the
degree of mediation (either as partial or complete medi-
ation), through a series of four models. Statistically sig-
nificant (p < 0.05) effects must be obtained in Models 1,
2, and 3 in order to test the full mediation model in
Model 4. Following this approach, four models were
estimated: (1) effect of treatment on ΔQ-LES-Q SF; (2)
effect of treatment on ΔMADRS; (3) effect of ΔMADRS
on ΔQ-LES-Q SF, independent of treatment; and (4) ef-
fect of treatment ΔQ-LES-Q SF, even when controlling
for the effect of ΔMADRS. ΔMADRS would be consid-
ered a partial mediator on the relationship between lura-
sidone and ΔQ-LES-Q SF if statistically significant
effects were achieved in all 4 models. Complete medi-
ation would be indicated if the effect of treatment on
ΔQ-LES-Q SF described in Model 4 was 0. Although the
Baron and Kenny model was originally implemented
using ordinary least squares regression, modern path
analysis methods were utilized in the current study
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following the Baron and Kenny steps in order to accur-
ately estimate the significance of the indirect effect.
Mplus statistical software version 7.0 [29] was used to
conduct all analyses for Models 1–4. The total effect (β1)
of the relationship between treatment and ΔQ-LES-Q
SF was estimated in Model 1. The direct effect of treat-
ment on the ΔQ-LES-Q SF controlling for ΔMADRS
(β4), and the indirect effect, were estimated in Model 4.
The indirect effect was calculated as the product of the re-
lationship between treatment and ΔQ-LES-Q SF (β2), and
the relationship between ΔMADRS to ΔQ-LES-Q SF (β3).
Bias-corrected bootstrapping was used to estimate the
standard errors for the estimation of the p-values to deter-
mine significance of each path, as well as the indirect
effect. The proportion of the effect that was mediated was
calculated as β2*β3/ β1, while the percentage of total
variance explained by each path was reported using the
standardized R2 values. The strength of the parameter es-
timates was interpreted using Kenny recommendations
for effect size estimates of small (0.02), medium (0.15),
and large (0.40) [30] for large samples with adequate
power for detecting an effect. For the analysis, each of the
models controlled for baseline score of the dependent
variable (i.e., Q-LES-Q SF or MADRS). Parameter esti-
mates with corresponding p-values were calculated for all
four models for both trials.
Overall model fit was assessed using various global fit
indices, where the following indices and fit values were
used as criteria to assess acceptable model fit: chi-square
test of overall model fit; Root Mean Square Error of Ap-
proximation (RMSEA) < 0.06 [31]; and Tucker Lewis Index
(TLI) and the Comparative Fit Index (CFI) > 0.90 [32].
Results
Demographics and baseline characteristics
In the monotherapy trial, 818 patients were screened, of
whom 505 (61.7 %) were randomly assigned to 6 weeks
of treatment and 485 (96.0 %) were included in the ITT
population. In the adjunctive therapy trial, a total of 672
patients were screened, of whom 348 (51.8 %) were
randomly assigned to 6 weeks of treatment and 340
(97.7 %) were included in the ITT population. Study
completion rates were similar for treatment and placebo
groups for monotherapy (74 %, 73 %, and 75 %) and
adjunctive therapy (78.1 % and 82.4 %) trials, respect-
ively, in addition to baseline demographic and clinical
characteristics for both studies (Table 1).
Efficacy results
Descriptive statistics for the Q-LES-Q SF at baseline and
at 6 weeks are presented in Tables 2, 3, and 4, along with
the corresponding change scores. For the monotherapy
trial, change scores on the Q-LES-Q SF indicating im-
provement was significantly larger for both lurasidone
20–60 mg/day (mean change = 21.9) and 80–120 mg/
day (mean change = 23.0) groups in comparison to
placebo (mean change = 14.5). Similar change was
demonstrated for adjunctive therapy for the lurasi-
done group (mean change = 23.3) in comparison to
the placebo group (mean change = 17.9).
In the ANCOVA analyses controlling for pooled study
center and baseline Q-LES-Q SF percentage maximum
score for the monotherapy trial, the least squares mean
(SE) change from baseline to 6 weeks on the Q-LES-Q
SF was significantly greater for lurasidone 20–60 mg/day
group (22.9 [1.5], p < 0.001) and 80–120 mg/day group
(22.7 [1.5], p < 0.01) in comparison to placebo (15.2
[1.5]). Similar findings were obtained in the adjunctive
therapy trial for the lurasidone group in comparison to
placebo (23.1 [1.5] versus 17.9 [1.6]; p <0.05).
Direct and indirect effects of lurasidone on HRQoL
The total effect between lurasidone treatment and
ΔQ-LES-Q SF in Model 1 was strong and statistically
significant in both trials (Table 5). Relationships
tested in Models 2 and 3 were also statistically sig-
nificant (all p < 0.05). Thus, the full mediation model
(Model 4) was analyzed and tested to determine if
there was an independent effect of treatment on ΔQ-
LES-Q SF after accounting for the variance explained
by ΔMADRS.
As shown in Fig. 1a and b (for monotherapy and adjunct-
ive therapy, respectively), lurasidone treatment predicted
improvement in MADRS (monotherapy = β2 = −0.44;
Table 1 Patient demographic characteristics at baseline











Age, mean (SD) 41.3 (12.3) 42.0 (12.4) 41.2 (12.4) 41.0 (11.5) 42.6 (11.8)
Male, n (%) 70 (43.5 %) 64 (39.5 %) 75 (46.3 %) 93 (52.0 %) 85 (52.8 %)
White, n (%) 107 (66.5 %) 106 (65.4 %) 107 (66.0 %) 108 (60.3 %) 102 (63.4 %)
Baseline Q-LES-Q SF Percentage Maximum Score,
mean (SD)
51.3 (20.8) 52.1 (20.0) 45.5 (20.5) 55.9 (19.6) 50.4 (20.6)
Baseline MADRS Total Score, mean (SD) 30.3 (5.0) 30.6 (4.9) 30.5 (4.9) 30.5 (5.3) 30.7 (4.8)
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adjunctive therapy: β2 = −0.34), which subsequently pre-
dicted improvement in HRQoL (monotherapy: β3 = −0.73;
adjunctive therapy: β3 = −0.75). However, the direct effect
of treatment on ΔQ-LES-Q SF after accounting for
ΔMADRS did not remain statistically significant in either
study, as the direct effect estimate was considered small
(monotherapy: β4 = 0.11, p = 0.13) to near 0 (adjunctive
therapy: β4 = 0.02, p = 0.77). This finding is reflected in the
indirect effects, estimated as 0.32 in the monotherapy
trial (p < 0.001) and 0.26 (p < 0.01) in the adjunctive
therapy trial. The percentage of variance accounted
for by the indirect effect through ΔMADRS was 73 %
and 91 %, respectively. For both studies, the full mediation
models with direct and indirect effects explained the ma-
jority of the variability in ΔQ-LES-Q SF (monotherapy:
R2 = 60.5 %; adjunctive therapy: R2 = 66.2 %). The findings
from this analysis provide evidence for partial mediation
in the monotherapy trial and almost complete medi-
ation in the adjunctive therapy trial.
Discussion
In this post-hoc analysis of two 6-week, randomized,
placebo-controlled clinical trials conducted to assess the
efficacy of lurasidone on HRQoL in patients with bipolar
depression, lurasidone performed significantly better in
comparison to placebo in improving patient-reported
HRQoL. In analyses of lurasidone as a monotherapy and
adjunctive therapy to lithium or valproate, similar
adjusted change in the Q-LES-Q SF was evidenced for
all treatment groups receiving lurasidone. The overall
findings provide evidence that lurasidone performs si-
milarly as a monotherapy and as an adjunctive therapy,
at a range of dosage levels, in improving self-reported
HRQoL in patients with bipolar depression.
While morbidity and mortality is high in patients with
bipolar depression and HRQoL is often greatly compro-
mised, improvement in HRQoL in clinical treatment
trials for bipolar depression is often understudied. How-
ever, the relatively few studies that have been published
provide support for the assertion that treatment can
improve HRQoL in patients with bipolar depression.
Using the Medical Outcomes Study 36-Item Short-
Form Health Survey (SF-36) as a measure of HRQoL
in an 8-week randomized, controlled trial of olanza-
pine or olanzapine-fluoxetine combination, Shi and
colleagues [33] found that patients receiving either
olanzapine or olanzapine-fluoxetine reported signifi-
cantly greater improvement on the mental and physical
component scores of the SF-36. More recently, Endi-
cott and colleagues [34] conducted a secondary ana-
lysis of two 8-week randomized, controlled clinical
trials of quetiapine. Using a mixed model for repeated
measures analysis, they found that patients taking 300
and 600 mg/day significantly improved on the Q-LES-
Q SF with adjusted least squares mean (SE) change
scores of 10.89 (0.59) and 12.14 (0.62), respectively, by
Week 8. These findings parallel earlier work where Q-
LES-Q SF scores were significantly improved in pa-
tients taking quetiapine in comparison to placebo at
Week 4 and Week 8 [35]. The present study demon-
strated that in controlled analyses, lurasidone was even
more effective in improving HRQoL as measured by
the Q-LES-Q SF, where mean (SD) change scores were
22.5 (16.9) and 23.3 (18.7) in the monotherapy and ad-
junctive therapy studies, respectively.
The HRQoL improvement in patients receiving lurasi-
done parallel the reduction in MADRS depression scores
in this sample [23, 24]. Specifically, both as a monotherapy
Table 2 Mean change for Q-LES-Q SF percentage maximum scores from baseline to 6 weeks: monotherapy (Lurasidone 20–60 mg/
day and Lurasidone 80–120 mg/day)
Lurasidone 20–60 mg/day Lurasidone 80–120 mg/day
N Mean (SD) N Mean Change (SD) P value N Mean (SD) N Mean Change (SD) P value
Q-LES-Q SF
Baseline 157 33.8 (13.7) – 160 33.5 (13.0) –
6-Weeks 123 55.9 (19.4) 120 21.9 (16.0) <.0001 121 56.8 (18.1) 120 23.0 (17.7) <.0001
All p-values for Q-LES-Q SF outcomes are based on t-tests comparing differences from baseline to 6 weeks within treatment group
Table 3 Mean change for Q-LES-Q SF percentage maximum scores from baseline to 6 weeks: monotherapy (combined lurasidone
treatment groups and placebo)
Combined treatment dose groups Placebo
N Mean (SD) N Mean Change (SD) P value N Mean (SD) N Mean Change (SD) P value
Q-LES-Q SF
Baseline 317 33.7 (13.4) – 160 34.2 (13.5) –
6-weeks 244 56.4 (18.7) 240 22.5 (16.9) <.0001 125 48.7 (20.7) 124 14.5 (17.0) <.0001
All p-values for Q-LES-Q SF outcomes are based on t-tests comparing differences from baseline to 6 weeks within treatment group
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and an adjunctive therapy, lurasidone treatment had a sig-
nificantly greater effect in reducing depression over 6
weeks in comparison to placebo as measured by the
MADRS and the Clinical Global Impressions-Bipolar
scale. Path analysis revealed that MADRS total score
improvement was a partial (monotherapy) and almost-
complete mediator (adjunctive therapy) on the relation-
ship between treatment and improvement in the Q-LES-
Q SF. Thus, improvement in HRQoL in lurasidone-
treated patients largely occurred through improvements
in depression symptoms. This finding of partial (rather
than full) mediation in the monotherapy trial could be
due to larger mean Q-LES-Q SF improvement resulting
from lurasidone administered as a monotherapy in
comparison to an adjunctive therapy. These findings
are supported by previous investigations comparing the
effects of monotherapy and combination therapy on
HRQoL using the investigator-rated global assessment
of functioning (GAF) in patients with bipolar disorder
[36, 37]. However, future research assessing the incre-
mental benefit of monotherapy over adjunctive therapy
on HRQoL improvement is needed in patients with bi-
polar depression.
This knowledge of both the direct and indirect effects
of lurasidone treatment on improvement in HRQoL
provides a more holistic view of the complex effect of
treatment on the magnitude and level of improvement
in how a patient feels or functions. Whereas the primary
goal of treatment for patients with bipolar depression is
often the alleviation of depression symptoms, improved
HRQoL is often critical to patients and their clinicians
[4], and could potentially shape long-term recovery. For
example, improved HRQoL has been associated with
greater adherence to treatment [38], which has been
shown to be a great barrier to effective long-term
treatment in patients with bipolar depression [39].
The results of the present study are supported by
previous investigations that have demonstrated that a
strong relationship exists between a depressed clinical
state and reduced HRQoL in patients with bipolar
disorder [34, 40–42]. For example, using data from the
Systematic Treatment Enhancement Program for Bipo-
lar Disorder (STEP-BD) multicenter trial, researchers
sought to determine the unique contribution of clinical
states (e.g., depression, mania/hypomania, mixed) in
relation to HRQoL. Bipolar patients with depression
had significantly lower HRQoL scores in comparison to
recovered, recovering, and patients with mania/hypo-
mania, controlling for sociodemographic and health
characteristics. Similar conclusions were drawn by
Saarni et al. [43] and Vojta [41], concluding that in
bipolar patients, depressive symptoms are the strongest
predictors of reduced HRQoL. Also using the Q-LES-Q
SF and MADRS to assess HRQoL and depression,
respectively, Endicott [34] found that improvement in
HRQoL across an 8-week period was most strongly
correlated with improvements in MADRS scores. In the
current study, we expanded on these analyses using
path analysis, finding that not only is change in these
constructs correlated across time, but that change in
MADRS is predictive of change in Q-LES-Q SF, thus
providing an assessment of the mediating effect of
depression on the treatment-HRQoL relationship.
Several study limitations should be noted. The study
duration was only 6 weeks, and a longitudinal study is
needed to determine if patients maintain the demon-
strated improvement or continue to improve over a longer
period of time. However, a 6-week trial length is a stand-
ard for acute depression clinical trials [44, 45]. In addition,
HRQoL was assessed based on patient-reported data, and
not direct observation of patient behavior or functioning,
and the assessment was conducted with only one assess-
ment of HRQoL. The findings from the current study
could be different if an alternative PRO of HRQoL was
selected. Finally, we used path analysis in a limited sample
to determine if depression mediated the treatment-
HRQoL relationship. A replication of these analyses in a
Table 4 Mean Change for Q-LES-Q SF percentage maximum scores from baseline to 6 weeks: adjunctive therapy (Lurasidone
20–120 mg/day and Placebo)
Lurasidone 20–120 mg/day Placebo
N Mean (SD) N Mean Change (SD) P value N Mean (SD) N Mean Change (SD) P value
Q-LES-Q SF
Baseline 177 36.1 (14.3) – 159 35.7 (13.5) –
6-Weeks 142 58.4 (181) 141 23.3 (18.7) <.0001 135 52.7 (19.9) 134 17.9 (20.2) <.0001
All p-values for Q-LES-Q SF outcomes are based on t-tests comparing differences from baseline to 6 weeks within treatment group
Table 5 Path analysis of models 1, 2, and 3 for monotherapy
and adjunctive therapy trials
Model Monotherapy β (p-value) Adjunctive therapy β (p-value)
Model 1 β1 = 0.45 (p < 0.001) β1 = 0.28 (p < 0.05)
Model 2 β2 = −0.41 (p < 0.01) β2 = −0.36 (p < 0.01)
Model 3 β3 = −0.77(p < 0.001) β3 = −0.75 (p < 0.001)
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larger population is needed to confirm our findings.
Although mediation analysis allows for the interpretation
of causal relationships from correlational data, additional
research using a causal study design is necessary to
validate these findings.
Conclusions
In summary, patients with bipolar depression have
greatly impaired HRQoL. Lurasidone as a monotherapy
(20–60 mg/day and 80–120 mg/day) and adjunctive to
lithium or valproate (20–120 mg/day) was efficacious in
improving HRQoL in this study. Change in HRQoL is
largely mediated by improvement in depression symp-
toms. These findings underscore the significance of
treatment effectiveness in reduction of depressive symp-
toms, which in turn result in improvement of HRQoL in
patients with bipolar depression.
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